Determinants of extraction efficiency in human amniotic membrane processing: biological, mechanical, and biochemical...

Human amniotic membrane extract (AME) contains growth factors that contribute to epithelial regeneration and immunomodulation. This review synthesizes current evidence and incorporates our recent preliminary experimental data to identify the critical parameters that influence the extraction efficiency of six key growth factors-EGF, HGF, TGF-β, bFGF, KGF, and NGF-from human amniotic membrane obtained via cesarean delivery. A comprehensive literature analysis was combined with empirical observations from our laboratory using cryogenic pulverization, differential buffer systems, protease inhibition strategies, and post-extraction stabilization techniques. Factor-specific biochemical behavior and matrix interactions were evaluated to outline optimized extraction conditions. Extraction efficiency was strongly dependent on: 1. preservation of epithelial and stromal integrity; 2. cryogenic pulverization for maximal cell lysis; 3. buffer composition, particularly the use of trehalose for protein stabilization; 4. heparin or high ionic strength solutions for releasing matrix-bound factors such as HGF, bFGF, and KGF; 5. EDTA-based protease control for NGF; and 6. sonication-assisted liberation of latent TGF-β complexes. Our practical study data confirm that an extraction protocol incorporating phosphate-buffered saline (PBS), trehalose, and cryo-milling substantially enhances the recovery of EGF, NGF, and TGF-β levels, while the addition of protease inhibitors to PBS and cryo-milling improves the concentrations of HGF, FGF, and TGF-β. AME yield is governed by a constellation of process-dependent variables that can be systematically optimized. Integrating biological tissue properties with precise mechanical and biochemical strategies enables the production of standardized, high potency extracts suitable for clinical and biobanking applications. Establishing these optimized conditions may support the development of GMP-compliant workflows and improve the therapeutic consistency of AME-based products.